Immunome, Inc. short interest in 2023
In 2023, Immunome, Inc.'s disclosed short interest ran from 0.94% of shares outstanding on 13 Jan 2023 to 1.59% on 15 Dec 2023, a change of +0.65 percentage points. The year's high was 2.00% on 31 Jul 2023 and its low 0.94% on 13 Jan 2023, averaging 1.42% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.34 days on 14 Apr 2023. Full history: Immunome, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.94% (13 Jan 2023)
- End of year
- 1.59% (15 Dec 2023)
- Change
- +0.65 pp
- High
- 2.00% (31 Jul 2023)
- Low
- 0.94% (13 Jan 2023)
- Average
- 1.42%
- Highest days to cover
- 10.34 (14 Apr 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.94% | 1.00 | |
| 31 Jan 2023 | 1.09% | 1.66 | |
| 15 Feb 2023 | 1.10% | 2.56 | |
| 28 Feb 2023 | 1.20% | 2.79 | |
| 15 Mar 2023 | 1.06% | 4.10 | |
| 31 Mar 2023 | 1.33% | 6.54 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 1.50% | 10.34 | |
| 28 Apr 2023 | 1.63% | 5.56 | |
| 15 May 2023 | 1.14% | 2.71 | 10-Q filed, results (8-K) |
| 31 May 2023 | 1.21% | 5.86 | |
| 15 Jun 2023 | 1.17% | 6.91 | |
| 30 Jun 2023 | 1.00% | 1.00 | |
| 14 Jul 2023 | 1.70% | 1.00 | |
| 31 Jul 2023 | 2.00% | 3.99 | |
| 15 Aug 2023 | 1.77% | 6.16 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 1.77% | 6.12 | |
| 15 Sep 2023 | 1.86% | 6.31 | |
| 29 Sep 2023 | 1.81% | 6.94 | |
| 13 Oct 2023 | 1.62% | 2.69 | |
| 31 Oct 2023 | 1.79% | 4.02 | |
| 15 Nov 2023 | 1.00% | 7.17 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 1.27% | 5.16 | |
| 15 Dec 2023 | 1.59% | 2.49 |
See also: Immunome, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.